REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Mass Builder Elite

Muscle Growthadvanced
29
Share
Peptides

4

Avg Daily mcg

3,957

Level

advanced

Added

May 16, 2026

Overview

The Mass Builder Elite is an advanced-tier, multi-pathway muscle growth protocol designed for experienced users seeking maximum hypertrophy through sustained growth hormone elevation, enhanced recovery, and mitochondrial energy optimization. This four-peptide stack creates overlapping GH secretion patterns while MOTS-c provides the metabolic substrate efficiency needed to convert elevated anabolism into actual tissue accrual. CJC-1295 at 2000mcg three times per week provides the foundation with sustained GH-releasing hormone activity that elevates baseline growth hormone and IGF-1 levels for days between injections. Ipamorelin at 300mcg twice daily layers sharp, clean GH pulses on top of this elevated baseline without triggering cortisol, prolactin, or excessive appetite stimulation. Sermorelin at 500mcg on a 5-days-on/2-days-off schedule adds a third GH-releasing pathway through direct anterior pituitary stimulation, with the cycling protocol preventing receptor desensitization. MOTS-c at 5000mcg three times per week enhances mitochondrial function, improves glucose uptake into muscle cells, and activates AMPK to optimize the energy metabolism required for intensive training and recovery. The layered approach to GH secretion in this stack produces superior results compared to any single secretagogue: CJC-1295 raises the floor, Ipamorelin creates acute peaks, and Sermorelin maintains pituitary sensitivity. MOTS-c ensures that the metabolic machinery can actually utilize the elevated anabolic signaling for productive muscle protein synthesis rather than fat storage. Administer CJC-1295 on non-consecutive evenings (e.g., Monday, Wednesday, Friday). Ipamorelin should be taken morning and evening on an empty stomach. Sermorelin is best administered before bed during active days, with weekends off. MOTS-c can be taken on training days, ideally pre-workout. This stack is suited for advanced trainees with at least 3-5 years of serious resistance training, established nutrition protocols exceeding 1g protein per pound of bodyweight, and previous peptide experience. The multiple GH pathways require monitoring for potential water retention and joint changes. Research supports the amplification effect of combining GHRH analogs with ghrelin mimetics, while MOTS-c studies demonstrate improved exercise capacity and metabolic efficiency. Run for 12-16 weeks with blood work at baseline, week 6, and conclusion. A 6-week break between cycles is recommended.

Dosing Protocol

CJC-1295

3 times per week

Read more about CJC-1295 →

2,000 mcg

per dose

Ipamorelin

Twice per day

Read more about Ipamorelin →

300 mcg

per dose

Sermorelin

5 days on/2 off

Read more about Sermorelin →

500 mcg

per dose

MOTS-c

3 times per week

Read more about MOTS-c →

5,000 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.